[go: up one dir, main page]

MX2018001673A - Peptido derivado de depdc1 y vacuna que lo contiene. - Google Patents

Peptido derivado de depdc1 y vacuna que lo contiene.

Info

Publication number
MX2018001673A
MX2018001673A MX2018001673A MX2018001673A MX2018001673A MX 2018001673 A MX2018001673 A MX 2018001673A MX 2018001673 A MX2018001673 A MX 2018001673A MX 2018001673 A MX2018001673 A MX 2018001673A MX 2018001673 A MX2018001673 A MX 2018001673A
Authority
MX
Mexico
Prior art keywords
peptide
present
provides
depdc1
cell
Prior art date
Application number
MX2018001673A
Other languages
English (en)
Inventor
YAMASHITA Sachiko
HIKICHI Tetsuro
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2018001673A publication Critical patent/MX2018001673A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La presente invención provee un péptido de epítopo derivado de DEPDC1 que tiene la capacidad de inducir células T citotóxicas. La presente invención también provee un polinucleótido que codifica el péptido, una célula presentadora de antígeno que presenta el péptido y una célula T citotóxica que hace blanco en el péptido, y un método de inducción de las células presentadoras de antígeno o CTL. La presente invención provee, además, composiciones y composiciones farmacéuticas que los contienen como ingrediente activo. Además, la presente invención provee un método de tratamiento o prevención del cáncer, o un método de prevención de la recurrencia postoperatoria del cáncer usando este péptido, polinucleótido, célula presentadora de antígeno o célula T citotóxica, o usando esta composición farmacéutica. También se provee un método de inducción de una respuesta inmunitaria contra el cáncer.
MX2018001673A 2015-08-12 2016-08-10 Peptido derivado de depdc1 y vacuna que lo contiene. MX2018001673A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015159291 2015-08-12
JP2015165779 2015-08-25
PCT/JP2016/073522 WO2017026503A1 (ja) 2015-08-12 2016-08-10 Ｄｅｐｄｃ１由来ペプチドおよびそれを含むワクチン

Publications (1)

Publication Number Publication Date
MX2018001673A true MX2018001673A (es) 2018-05-07

Family

ID=57984456

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018001673A MX2018001673A (es) 2015-08-12 2016-08-10 Peptido derivado de depdc1 y vacuna que lo contiene.
MX2022006022A MX2022006022A (es) 2015-08-12 2018-02-08 Peptido derivado de depdc1 y vacuna que lo contiene.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006022A MX2022006022A (es) 2015-08-12 2018-02-08 Peptido derivado de depdc1 y vacuna que lo contiene.

Country Status (13)

Country Link
US (2) US10676508B2 (es)
EP (1) EP3336186A4 (es)
JP (1) JP6934250B2 (es)
KR (1) KR20180033585A (es)
CN (2) CN112961213A (es)
AU (2) AU2016306527B2 (es)
CA (1) CA2994929A1 (es)
IL (2) IL257335B (es)
MX (2) MX2018001673A (es)
RU (2) RU2022100330A (es)
SG (2) SG11201800895VA (es)
TW (1) TWI769984B (es)
WO (1) WO2017026503A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535270A (ja) * 2016-11-18 2019-12-12 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のためのＤＥＰＤＣ１エピトープペプチドおよびこれを含有するワクチン
TW202023581A (zh) * 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CN109321656B (zh) * 2018-10-22 2021-10-01 上海交通大学医学院附属仁济医院 蛋白depdc1作为诊断三阴乳腺癌的标记物的用途
GB201917699D0 (en) * 2019-12-04 2020-01-15 Ultimovacs Ab Vaccine conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3738395B2 (ja) 1991-08-26 2006-01-25 エピミューン，インコーポレイティド Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ
ZA926441B (en) 1991-08-26 1993-06-07 Cytel Corp HLA-restricted hepatitis B virus CTL epitopes.
CN1122576A (zh) 1993-03-11 1996-05-15 南加利福尼亚大学 免疫感染簇病毒感染的治疗策略
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7001999B1 (en) 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US20050123938A1 (en) 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
AU2001286699A1 (en) 2000-08-22 2002-03-04 Agensys, Inc. Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers
CA2425827A1 (en) 2000-10-12 2002-04-18 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1911461B1 (en) 2000-10-19 2011-12-07 Epimmune Inc. HLA class I and II binding peptides and their uses
EP1356048A2 (en) 2000-12-04 2003-10-29 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
JP2005515779A (ja) 2002-01-31 2005-06-02 ワイス アグレカナーゼ分子
AU2003222103A1 (en) 2002-03-28 2003-10-13 Idec Pharmaceuticals Corporation Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
EP2927322A1 (en) * 2004-06-10 2015-10-07 Viventia Bio Inc. Tumor specific antibody
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
EP2298895A1 (en) 2005-07-27 2011-03-23 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
CA2660286A1 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
SG175566A1 (en) * 2006-10-17 2011-11-28 Oncotherapy Science Inc Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
JP5640263B2 (ja) 2008-08-28 2014-12-17 オンコセラピー・サイエンス株式会社 Ｄｅｐｄｃ１ポリペプチドを使用した膀胱癌の治療または予防のための方法
WO2011096210A1 (en) 2010-02-03 2011-08-11 Oncotherapy Science, Inc. Prmt1 and prmt6 for target genes of cancer therapy and diagnosis
US20190346442A1 (en) * 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction

Also Published As

Publication number Publication date
JP6934250B2 (ja) 2021-09-15
CN108138170B (zh) 2022-01-25
TW201718624A (zh) 2017-06-01
AU2016306527B2 (en) 2022-03-17
SG11201800895VA (en) 2018-03-28
US10676508B2 (en) 2020-06-09
WO2017026503A1 (ja) 2017-02-16
EP3336186A4 (en) 2019-03-06
CA2994929A1 (en) 2017-02-16
KR20180033585A (ko) 2018-04-03
AU2016306527A2 (en) 2018-03-29
TWI769984B (zh) 2022-07-11
RU2018108197A (ru) 2019-09-12
EP3336186A1 (en) 2018-06-20
IL257335A (en) 2018-03-29
JPWO2017026503A1 (ja) 2018-05-31
US20200308224A1 (en) 2020-10-01
US20180222941A1 (en) 2018-08-09
US11673915B2 (en) 2023-06-13
AU2022202751A1 (en) 2022-05-19
IL257335B (en) 2022-08-01
RU2018108197A3 (es) 2020-07-20
IL284792A (en) 2021-08-31
AU2016306527A1 (en) 2018-02-22
SG10201913592QA (en) 2020-02-27
RU2765574C2 (ru) 2022-02-01
MX2022006022A (es) 2022-06-22
RU2022100330A (ru) 2022-01-19
CN108138170A (zh) 2018-06-08
CN112961213A (zh) 2021-06-15

Similar Documents

Publication Publication Date Title
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
MY187540A (en) Compounds active towards bromodomains
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
MX2018001673A (es) Peptido derivado de depdc1 y vacuna que lo contiene.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX362912B (es) Péptidos ube2t y vacunas que incluyen los mismos.
MX2018004308A (es) Peptido derivado de foxm1 y vacuna que lo incluye.
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017001649A (es) Peptido derivado de koc1 y vacuna que lo incluye.
MX2021001357A (es) Peptido derivado de cdca1 y vacuna que lo contiene.
MX2017001650A (es) Peptido derivado de cdca1 y vacuna que lo contiene.
AR106501A1 (es) Adyuvante y composición de vacuna que lo contiene
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
EP3848383A3 (en) Urlc10-derived peptide and vaccine containing same
MX2018004305A (es) Peptido derivado de mphosph1 y vacuna que lo incluye.
SV2016005348A (es) Mã‰todos para tratar infecciones
UY35730A (es) Composiciones farmacéuticas comprendiendo kisspeptin o sus derivados